Fig. 1From: Sequential and co-occurring DNA damage response genetic mutations impact survival in stage III colorectal cancer patients receiving adjuvant oxaliplatin-based chemotherapyAn example of dMMR colorectal cancer stained with hematoxylin-eosin (a, b). The cancer cells revealed loss of nuclear staining of MLH1 (c) and PMS2 (d), and preserved nuclear staining of MSH2 (e) and MSH6 (f) (100x)Back to article page